Novartis Shares Plunge After Late-Stage Drug Trial Fails to Meet Targets

Novartis stock dropped sharply after the company reported that its late-stage trial for del-desiran failed to achieve its primary efficacy endpoints. The setback triggered a broader sell-off across the biopharmaceutical sector and raised concerns about the company’s development pipeline.

8 Sept, 05:48 — 8 Sept, 13:53

Post Share

Why this matters

Novartis’s heavy reliance on external acquisitions like Avidity has become a high-stakes strategy in an industry where internal R&D success rates are declining. Repeated late-stage failures threaten shareholder confidence, potentially impacting dividend sustainability and limiting capital for future innovation. Investors are closely watching whether this signals a temporary stumble or a fundamental shift in the company’s development capabilities.

Key entitiesNovartis del-desiran Avidity Biosciences Dyne Therapeutics Sarepta Therapeutics

The Story

What 13 sources agree on, dispute, and miss

What sources agree on

Novartis shares fell between 10% and 13% following the trial results
The failed candidate was del-desiran, a neuromuscular treatment
This represents the company’s third clinical trial setback in one week
Novartis previously acquired Avidity Biosciences for roughly $12 billion

Key claims4 agreed · 1 unverified

✓

Novartis shares declined between 10% and 13% on the day of the announcement

agreed·bloombergseeking-alphacnbc20-minuten

✓

The failed medication was named del-desiran

agreed·bloombergcnbcReuterswsj

✓

This trial failure marks Novartis's third clinical setback within a seven-day period

agreed·bloombergcnbcFT

The stock decline negatively impacted peer biotechnology companies including Dyne Therapeutics and Sarepta Therapeutics

unverified·seeking-alpha

✓

Novartis completed its acquisition of Avidity Biosciences for approximately $12 billion

agreed·bloomberg

Where they diverge

Strategic vs. operational framing of the failure

bloombergwsj

Frames the setback through the lens of capital allocation and the strategic risks of the $12B Avidity acquisition

FTcnbc

Emphasizes chronic pipeline weakness and repeated clinical misfires as signs of deeper R&D dysfunction

Market contagion emphasis

seeking-alpha

Highlights immediate spillover effects, noting how the drop dragged down peer biotechs like Dyne and Sarepta

Reutersmorningstar

Focuses exclusively on Novartis’s internal valuation and dividend implications without discussing sector-wide contagion

Coverage gaps

Specific regulatory next steps or potential FDA advisory committee discussions

ReportedFT

MissingbloombergcnbcReuters+1

Detailed breakdown of the $12B Avidity deal terms and integration status

Reportedbloomberg

MissingFTcnbcReuters+1

Coverage matrix(13 sources)

1–10 of 13

	Reuters	bloomberg	wsj	FT	cnbc	globe-and-mail	marketwatch	morningstar	index-hr	Yahoo
Strategic vs. operational framing of the failure
Market contagion emphasis
Specific regulatory next steps or potential FDA advisory committee discussions
Detailed breakdown of the $12B Avidity deal terms and integration status

Covered Divergent Not mentioned

The Story

Analyzing sources…

Source Diversity

Excellent (76/100)

13 sources33/33

Spectrum spread— 3/5 buckets covered17/33

Far L

Left4

Left (4)

Yahooglobe-and-mailcnbcindex-hr

Center7

Center (7)

marketwatchbloombergFT20-minuteninvesting-comReutersmorningstar

Right2

Right (2)

seeking-alphawsj

Far R

Geographic diversity— 6 regions26/34

US8Canada1UK1Switzerland1Croatia1Intl1

Political spectrum

LeftCenterRight

index-hr

cnbc

bloomberg

20-minuten

investing-com

reuters

morningstar

seeking-alpha

wsj

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

index-hrcenter-leftcenterneutral—irrelevant content unrelated to pharmaceuticals

cnbccentercenter-lefturgentMostly Factualurgent market language emphasizing volatility

bloomberg

Coverage leans: center

Coverage maintains a predominantly market-focused, institutional tone typical of financial journalism, with minor variations in urgency and strategic emphasis reflecting standard business reporting rather than partisan ideology.

Sources

Showing 8 of 13 sources

ReutersVery High12h ago

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis faces fresh blow to pipeline with del-desiran drug setback reuters.com

Read full article →

bloombergHigh8h ago

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)

Read full article →

cnbcMostly Factual10h ago

Pharma major plummets over 10% after third trial disappointment in a week

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Read full article →

globe-and-mailHigh6h ago

Novartis shares fall after second major trial setback in days

Failed clinical trial for recently acquired drug del-desiran piles pressure on Swiss drugmaker’s pipeline and CEO

By Bhanvi Satija and Dave Graham and Marleen Kaesebier

Read full article →

marketwatchMostly Factual4h ago

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

By Jaimy Lee

Read full article →

morningstar12h ago

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial Morningstar

Read full article →

seeking-alphaMixed9h ago

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Read full article →

investing-com10h ago

Why is Novartis stock tumbling today?

By Investing.com

Read full article →

Coverage Timeline

First report: morningstar · 8 Sept, 05:48|Full coverage: 13 · 11h|Window: 11h

Left-leaningCenterRight-leaning

morningstar8 Sept, 05:48First to report

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

wsj8 Sept, 05:54

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - WSJ

Reuters8 Sept, 06:05

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

1h later

index-hr8 Sept, 07:28

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

1h later

bloomberg8 Sept, 10:13

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

2h later

globe-and-mail8 Sept, 12:01

Novartis shares fall after second major trial setback in days

2h later

marketwatch8 Sept, 13:53

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

3h later

Yahoo8 Sept, 17:08Latest update

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

Story evolution

The narrative quickly evolved from a straightforward clinical update to a broader assessment of Novartis’s acquisition-driven growth model and near-term financial stability.

Initial DisclosureSept 8, 05:48–06:05 UTC

Reuters and WSJ publish breaking reports confirming the del-desiran trial missed its primary endpoint

Market ReactionSept 8, 07:28–08:41 UTC

Financial networks and exchanges report a sharp 10–13% share price drop as trading opens

Strategic & Sector AnalysisSept 8, 08:56–10:13 UTC

Outlets contextualize the miss against the $12B Avidity acquisition and note spillover effects on peer biotechs

Novartis Shares Plunge After Late-Stage Drug Trial Fails to Meet Targets

Why this matters

The Story

What sources agree on

Key claims4 agreed · 1 unverified

Where they diverge

Coverage gaps

Coverage matrix(13 sources)

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Pharma major plummets over 10% after third trial disappointment in a week

Novartis shares fall after second major trial setback in days

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Why is Novartis stock tumbling today?

Coverage Timeline

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - WSJ

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Brašno čuvate u originalnoj vrećici? Zašto to i nije najbolja ideja

Pharma major plummets over 10% after third trial disappointment in a week

Why is Novartis stock tumbling today?

Studie verfehlt Hauptziel: Mega-Absturz von Novartis-Aktie

Novartis shares slide after drug for muscular disease fails trial

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis shares fall after second major trial setback in days

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

Story evolution

Related Stories

Glastonbury announces ticket sale dates with record £400 price

GameStop shares rise on strong quarterly earnings beat

Volkswagen to Convert German Plant into Defense Manufacturing Hub

EasyJet Sued for $72 Million Over Abandoned Aircraft in Sanctions Dispute

Why this matters

The Story

What sources agree on

Key claims4 agreed · 1 unverified

Where they diverge

Coverage gaps

Coverage matrix(13 sources)

Story evolution

Political spectrum